BioElectronics Corporation Logo

BioElectronics Corporation

BIEL

(0.0)
Stock Price

0,00 USD

0% ROA

5.5% ROE

0x PER

Market Cap.

0,00 USD

0% DER

0% Yield

-204.42% NPM

BioElectronics Corporation Stock Analysis

BioElectronics Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioElectronics Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

BioElectronics Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioElectronics Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BioElectronics Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioElectronics Corporation Revenue
Year Revenue Growth
2013 665.510
2014 1.289.896 48.41%
2015 2.339.646 44.87%
2016 2.089.694 -11.96%
2017 1.763.765 -18.48%
2018 1.045.873 -68.64%
2019 941.761 -11.06%
2020 829.563 -13.52%
2021 1.609.460 48.46%
2022 707.412 -127.51%
2023 714.708 1.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioElectronics Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2013 216.665
2014 360.449 39.89%
2015 506.424 28.82%
2016 384.928 -31.56%
2017 389.812 1.25%
2018 496.931 21.56%
2019 658.481 24.53%
2020 483.892 -36.08%
2021 327.727 -47.65%
2022 232.920 -40.7%
2023 272.448 14.51%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioElectronics Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 1.186.565
2014 1.073.556 -10.53%
2015 1.366.605 21.44%
2016 1.484.403 7.94%
2017 1.146.893 -29.43%
2018 879.559 -30.39%
2019 791.044 -11.19%
2020 672.121 -17.69%
2021 352.497 -90.67%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioElectronics Corporation EBITDA
Year EBITDA Growth
2013 -1.880.268
2014 -1.883.031 0.15%
2015 -1.775.500 -6.06%
2016 -1.396.980 -27.1%
2017 -1.358.040 -2.87%
2018 -2.033.440 33.21%
2019 -1.330.390 -52.85%
2020 -1.047.430 -27.01%
2021 -154.450 -578.17%
2022 -343.450 55.03%
2023 -274.290 -25.21%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioElectronics Corporation Gross Profit
Year Gross Profit Growth
2013 234.786
2014 545.080 56.93%
2015 1.330.744 59.04%
2016 1.255.456 -6%
2017 995.844 -26.07%
2018 355.192 -180.37%
2019 528.859 32.84%
2020 506.172 -4.48%
2021 795.532 36.37%
2022 486.517 -63.52%
2023 466.388 -4.32%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioElectronics Corporation Net Profit
Year Net Profit Growth
2013 -2.445.620
2014 -2.677.329 8.65%
2015 -2.450.249 -9.27%
2016 -2.106.723 -16.31%
2017 -2.118.793 0.57%
2018 -2.988.344 29.1%
2019 -2.325.279 -28.52%
2020 -1.159.722 -100.5%
2021 -289.821 -300.15%
2022 -784.910 63.08%
2023 -722.812 -8.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioElectronics Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioElectronics Corporation Free Cashflow
Year Free Cashflow Growth

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioElectronics Corporation Operating Cashflow
Year Operating Cashflow Growth

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioElectronics Corporation Capital Expenditure
Year Capital Expenditure Growth

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioElectronics Corporation Equity
Year Equity Growth

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioElectronics Corporation Assets
Year Assets Growth

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioElectronics Corporation Liabilities
Year Liabilities Growth

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioElectronics Corporation Dividends
Year Dividends Growth

BioElectronics Corporation Profile

About BioElectronics Corporation

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

CEO
Ms. Kelly A. Whelan
Employee
0
Address
4539 Metropolitan Court
Frederick, 21704

BioElectronics Corporation Executives & BODs

BioElectronics Corporation Executives & BODs
# Name Age
1 Ms. Kelly A. Whelan
Chief Executive Officer, President, Treasurer & Executive Director
70
2 John R. Martinez
Secretary & Vice President of Engineering
70
3 Mr. Andrew J. Whelan
Founder
70
4 Mr. Keith E. Nalepka
Vice President of Sales & Marketing and Executive Director
70

BioElectronics Corporation Competitors